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Abstract A feedback model was developed to describe the tolerance and oscil-
latory rebound seen in non-esteriﬁed fatty acid (NEFA) plasma concentrations
following intravenous infusions of nicotinic acid (NiAc) to male Sprague-Dawley
rats. NiAc was administered as an intravenous infusion over 30 min (0, 1, 5 or
20 lmol kg
-1 of body weight) or over 300 min (0, 5, 10 or 51 lmol kg
-1 of body
weight), to healthy rats (n = 63), and serial arterial blood samples were taken for
measurement of NiAc and NEFA plasma concentrations. Data were analyzed using
nonlinear mixed effects modeling (NONMEM). The disposition of NiAc was
described by a two-compartment model with endogenous turnover rate and two
parallel capacity-limited elimination processes. The plasma concentration of NiAc
was driving NEFA (R) turnover via an inhibitory drug-mechanism function acting
on the formation of NEFA. The NEFA turnover was described by a feedback model
with a moderator distributed over a series of transit compartments, where the ﬁrst
compartment (M1) inhibited the formation of R and the last compartment (MN)
stimulated the loss of R. All processes regulating plasma NEFA concentrations were
assumed to be captured by the moderator function. The potency, IC50, of NiAc was
45 nmol L
-1, the fractional turnover rate kout was 0.41 L mmol
-1 min
-1 and the
turnover rate of moderator ktol was 0.027 min
-1. A lower physiological limit of
NEFA was modeled as a NiAc-independent release (kcap) of NEFA into plasma and
was estimated to 0.032 mmol L
-1 min
-1. This model can be used to provide
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DOI 10.1007/s10928-010-9172-2information about factors that determine the time-course of NEFA response fol-
lowing different modes, rates and routes of administration of NiAc. The proposed
model may also serve as a preclinical tool for analyzing and simulating drug-
induced changes in plasma NEFA concentrations after treatment with NiAc or NiAc
analogues.
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Introduction
Elevated circulating concentrations of non-esteriﬁed fatty acids (NEFA) are now
recognized as a risk factor in myocardial infarction and occur in patients with
myocardial ischemia [1, 2]. Nicotinic acid (NiAc), a lipid lowering agent discovered
in the 1950s, inhibits lipolysis in adipose tissue by activating the GPR109A receptor,
resulting in a pronounced decrease in plasma concentrations of NEFA [3, 4]. NiAc
treatment has been associated with a decrease in cardiovascular events such as
myocardial infarction and death [5–7], and to date NiAc is one of few approved drugs
that diminishes both low-density lipoprotein (LDL) and triglycerides (TG) and
simultaneously elevates high-density lipoprotein (HDL) [7, 8]. Although NiAc has
been used for years, its pharmacokinetics and pharmacodynamics are not fully
understood. Following NiAc treatment, the change in plasma NEFA concentrations
is biphasic, with an initial depression being followed by a rebound elevation to
supernormal concentrations when NiAc is eliminated [9]. Furthermore, because of
tolerance development there is time dependence in the reduction of plasma NEFA
concentrations. For these reasons, it is necessary to clarify the rate and extent of
tolerance and rebound development of NEFA with respect to NiAc exposure when
optimizing new GPR109A agonists aimed at reducing NEFA.
There have been several approaches to modeling tolerance and rebound including
pool/precursor models [10–12], hypothetical counteracting metabolite models [13],
and feedback turnover models [14–18]. In this study the latter class of models is
applied to the NiAc-induced changes in plasma NEFA concentrations given that
these models have proven to be ﬂexible for characterization of the onset, intensity
and duration of response [17].
In 2009, our group published a dose-response-time analysis of data from studies
where NiAc was administered to rats with different infusion regimens and the
changes in plasma NEFA concentrations were measured [18]. The NEFA datasets
analyzed were originally designed to qualitatively assess the behavior of plasma
NEFA concentrations after different NiAc provocations, rather than for quantitative
analysis. As a result, the sampling schedule was intended to detect the maximum
and minimum response to NiAc, and to demonstrate the rebound phenomenon. The
data collected were more of an exploratory nature than for regression purposes.
Furthermore, it was not possible to obtain complete concentration-time proﬁles of
NiAc and NEFA. In the present study, we have reﬁned the experimental design in
order to describe the NiAc-NEFA system more thoroughly.
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functional adaptation (tolerance) and oscillatory rebound seen in NEFA plasma
concentrations following intravenous infusion of NiAc at varying rates and duration
to Sprague-Dawley rats. Secondary aims were to study the impact of tolerance
through graphically visualizing the equilibrium condition for this complex system in
relation to the corresponding non-tolerant system, and to describe the nonlinear
disposition of NiAc, including its endogenous synthesis.
Materials and methods
Chemicals
Nicotinic acid (pyridine-3-carboxylic acid) was obtained from Sigma-Aldrich
(St. Louis, MO, USA) and was dissolved in 0.9% NaCl. All solvents were of
analytical grade and the water used in the experiments was obtained from a water
puriﬁcation system (Elgastat Maxima, ELGA, Lane End, UK).
Animals and surgical procedures
Male Sprague-Dawley rats (Harlan Nederlands B.V.; n = 63) weighing 220–367 g
were housed and acclimatized in pairs for at least one week prior to surgery. They
had free access to standard rodent chow (R3, Laktamin AB, Stockholm, Sweden)
and tap water, and were kept in climate-controlled facilities at a room temperature
of 20–22C and relative humidity of 40–60% under a 12:12-h light–dark cycle
(lights on at 6:00 am). The study was approved by the Ethics Committee for Animal
Experiments, Gothenburg, Sweden (EA 100868).
Surgery was performed under isoﬂurane (Forene
, Abbott Scandinavia AB,
Solna, Sweden) anesthesia and body temperature was maintained at 37C using a
thermoregulated heating pad. Catheters were implanted in the left carotid artery for
blood sampling and in the right external jugular vein for drug administration,
according to the method of Popovic et al. [19]. Prior to cannulation, catheters
(Intramedic
, PE50, Becton, Dickinson and Company, Franklin Lakes, USA) were
ﬁlled with sterile sodium-citrate solution (20.6 mM sodium-citrate in sterile saline;
Pharmaceutical and Analytical R&D, AstraZeneca, Mo ¨lndal, Sweden) to prevent
clotting. After cannulation, the catheters were exteriorized at the nape of the neck
and sealed. After surgery, the rats were housed individually and allowed 5–8 days to
recover before initiation of the experiments.
Experimental design
The animals were fasted for 14 h prior to dosing and throughout the experiment to
minimize the ﬂuctuations in NEFA caused by food intake. They had free access to
drinking water during the length of fast. On the day of experimentation, they were
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pumps (CMA 100, Carnegie Medicin AB, Stockholm, Sweden). Following a 30 min
adaptation period, two consecutive arterial blood samples were collected 15 and
5 min prior to drug administration for determining predose baseline NEFA and
NiAc concentrations.
Animals were assigned to 8 groups, each of which received an intravenous
constant rate infusion for either 30 or 300 min. Four groups received vehicle (0.9%
NaCl, n = 10), or 1 (n = 4), 5 (n = 8) or 20 (n = 9) lmol kg
-1 NiAc over 30 min.
The remaining groups received vehicle (n = 8), or 5 (n = 9), 10 (n = 8) or 51
(n = 7) lmol kg
-1 NiAc over 300 min. The concentrations of the dosing solutions
were adjusted to give infusion volume ﬂow rates in the range of 3.5–22 lL min
-1,
based on body weight. The dosing solutions were prepared within 30 min of
administration by dissolving an appropriate amount of NiAc in saline solution.
Multiple (11–13 per rat) arterial blood samples were drawn at 2, 5, 10, 20, 28, 32,
35, 40, 45, 50, 55, 65, 85, 100 min for the 30 min infusion experiments and at 5, 20,
60, 120, 150, 180, 240, 299, 305, 315, 320, 325, 340, 360, 400, 420, 460 and
500 min for the 300 min infusion experiments for analysis of NiAc and NEFA
plasma concentrations. The total blood volume removed did not exceed 1.5 mL, and
was replaced with an equal volume of sterile sodium-citrate solution to maintain a
constant circulatory volume. The control rats received the same volume of infusion
solution (vehicle) as the NiAc groups, and all animals were subjected to similar
sampling procedures. The blood samples (120 lL) were collected in EDTA coated
polyethylene tubes and kept on ice until centrifuged (10,0009g, 5 min, 4C). The
plasma was stored at -20C pending analysis. The start of infusion was taken as
time zero (0 min).
Analytical assays
Analysis and quantiﬁcation of NiAc in plasma were done using LC-MS. The high
performance liquid chromatography (HPLC) system was an Agilent 1100 Series
(Hewlett-Packard GmbH, Walbronn, Germany) coupled to an HTC PAL auto-
sampler (CTC Analytics AG, Zwingen, Germany). Plasma samples (50 lL per
sample) were precipitated with cold acetonitrile containing 0.2% formic acid
(150 lL per sample). After vortex mixing and centrifugation at 4C (4,0009g,
20 min), an aliquot of 100 lL of the supernatant was used for analysis. The mobile
phase consisted of (A) 2% acetonitrile and 0.2% formic acid in water, and (B) 0.2%
formic acid in acetonitrile. Separation was performed on a 50 9 2.1 mm Biobasic
AX column with 5 lm particles (Thermo Hypersil-Keystone, Runcorn, Cheshire,
UK) with a gradient of 95–20% B over 1 min, held at 20% B for 1.5 min, and
returned to initial conditions in one step. The HPLC system was connected to a
Sciex API 4000 quadrupole mass spectrometer with a positive electrospray
ionization interface (Applied Biosystems, Ontario, Canada) and the mass transition
was 124.0[80.2. Data acquisition and data evaluation were performed using
Analyst 1.4.1 (Applied Biosystems). The method showed linearity over a
concentration range of 0.001–28 lmol L
-1. The lower limit of quantiﬁcation
(LLOQ) was 1 nmol L
-1 applying a sample volume of 50 lL plasma.
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123Plasma NEFA was analyzed using an enzymatic colorimetric method (Wako
Chemicals GmbH, Neuss, Germany) adapted to a 96-well format [18].
Disposition model of NiAc
NiAc is derived from the essential amino acid tryptophan [20]. Endogenous levels
of NiAc were detected in a number of predose and control animal samples. The full
disposition of NiAc was elucidated by means of exogenous input of the agonist. The
aim of modeling NiAc concentration-time data was to obtain individually ﬁtted
time-courses that could drive the NEFA concentration-time data. One-compartment
models with linear or nonlinear elimination and two-compartment models with
linear intercompartmental distribution and linear, nonlinear, parallel linear and
nonlinear, or two parallel nonlinear elimination processes from the central
compartment, were evaluated. Based on goodness-of-ﬁt (objective function value,
OFV) and parameter precision, a two-compartment disposition model with two
parallel capacity-limited elimination processes, likely corresponding to glycine
conjugation and amidation, and endogenous synthesis (Synt) of NiAc was selected
(Fig. 1).
The disposition model of NiAc was mathematically described by:
Vc
dCp
dt
¼ Inf þ Synt  
Vmax1
Km1 þ Cp
Cp  
Vmax2
Km2 þ Cp
Cp   CldCp þ CldCt ð1aÞ
Vt
dCt
dt
¼ CldCp   CldCt ð1bÞ
Fig. 1 Schematic illustration of
the feedback model describing
the NiAc-induced changes in
NEFA. Cp and Ct denote the
NiAc concentrations in plasma
and the peripheral compartment.
The NiAc disposition
parameters are Vc, Vt, Vmax1,
Km1, Vmax2, Km2, Cld, Inf, and
Synt (deﬁnitions in Table 1).
NEFA and M1;...;N denote the
response and moderator
compartments. The NEFA
turnover parameters are R0, kout,
ktol, kcap, p, IC50 and c
(deﬁnitions in Table 2). I(Cp)i s
deﬁned in Eq. 2. The number of
moderator transit compartments
N was 8. The solid and dashed
lines represent ﬂuxes and control
processes, respectively
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compartment, Vc and Vt the central and peripheral volume of distribution, Inf the
drug infusion rate, Synt the endogenous synthesis rate, Vmax1 and Km1 the maximal
velocity and Michaelis–Menten constant of the high afﬁnity process, Vmax2 and Km2
the maximal velocity and Michaelis–Menten constant of the low afﬁnity process,
and Cld the intercompartmental distribution. The endogenous concentration of NiAc
was estimated according to Eq. 12 in Appendix A.
Equations 1a and 1b were implemented into the nonlinear mixed effects
modeling (NONMEM) program and ﬁtted to the experimental data.
Feedback model of NEFA
According to the mechanism of action [21–23], NiAc affects plasma NEFA
concentrations by inhibition of hydrolysis of TG to NEFA and glycerol in
adipocytes, thereby reducing the release of NEFA into plasma. The inhibitory drug
mechanism function was described by:
IC p
  
¼ 1  
ImaxCc
p
IC
c
50 þ C
c
p
ð2Þ
where Imax,I C 50 and c are the maximum drug-induced inhibitory effect, plasma
concentration at 50% reduction of maximal effect (potency), and sigmoidicity
factor.
The feedback was modeled as a moderator distributed over a series of transit
compartments where the moderator in the ﬁrst compartment, M1, inhibited the
formation of R (i.e. the build-up of NEFA concentrations). The eighth moderator
compartment, M8, stimulated the loss of R. The dual-action of insulin on NEFA
regulation is captured by M1 and M8, where M1 denotes the rapid inhibition of
the hydrolysis of TG to NEFA and glycerol and M8 the delayed stimulation of
re-esteriﬁcation of NEFA to TG [24–27]. The moderator was affected by R via a
ﬁrst-order process ktolR and each transduction step used the same transit time
1/ktol. When NiAc inhibits the formation of R, R decreases; consequently the
production of moderator M1 will decrease. Since the formation of NEFA is inversely
proportional to the moderator raised to the power of p (M1
p), the formation of NEFA
will thus increase. After a delay, the level of moderator in the ﬁnal compartment,
M8, will also drop, resulting in a smaller loss of NEFA. Eventually the
concentrations of R and Mi (where i ¼ 1;...;8) will equilibrate.
The hydrolysis of TG to NEFA and glycerol is catalyzed by hormone sensitive
lipase (HSL) in adipocytes and by lipoprotein lipase in capillaries. NEFA
produced in the capillaries can diffuse into the interstitial space and reach the
adipocytes [24]. A fraction of NEFA will remain in the circulation, unaffected by
NiAc, representing the lower physiological limit of NEFA in plasma. The
hydrolysis of NEFA in the capillaries is incorporated in the model as a zero-order
production term, kcap:
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dt
¼ kin
1
M
p
1
IC p
  
þ kcap   koutRM8 ð3Þ
where M1 is the moderator in compartment one, M8 the moderator in compartment
eight, kin the turnover rate, p the ampliﬁcation factor, I(Cp) the inhibitory drug
function, kcap the formation of NEFA in capillaries and kout the fractional turnover
rate. The turnover of the moderators was given by:
dM1
dt
¼ ktol R   M1 ðÞ ð 4aÞ
dM2
dt
¼ ktol M1   M2 ðÞ ð 4bÞ
. .
.
dM8
dt
¼ ktol M7   M8 ðÞ ð 4cÞ
The relationship between R and moderator Mi at baseline becomes R0 = Mi,0 and
the turnover rate kin as a function of R0 (the baseline NEFA concentration), kout and
kcap becomes:
kin ¼ koutR2
0   kcap
  
R
p
0 ð5Þ
Initial parameter estimates and model selection
The initial estimates of R0, kout,k cap, ktol and IC50 were derived graphically. The
baseline concentration R0 was based on the predose level of NEFA. Following a
high dose of NiAc (Cp   IC50), Eq. 3 can be approximated by:
dR
dt
  kcap   koutRM8 ð6Þ
Provided kcap is initially much less than koutRR0, Eq. 6 can be simpliﬁed to:
dR
dt
   koutRR0 ð7Þ
where M8 is approximated to R0. Thus, the initial downswing of R on a semi-
logarithmic plot gives a slope of -koutR0.The lower physiological limit of NEFA
was reached following the highest dose of NiAc. This allows us to estimate kcap
from:
kcap   koutR2
ss ð8Þ
where Rss denote the steady state response.
We assume that an initial estimate of ktol may be approximated from the log-
linear decline of NEFA post-rebound time-course according to Eq. 30 in Appendix
C. The IC50 was approximated as the concentration of NiAc resulting in a half-
maximal response following a 30 min infusion. The sigmoidicity (c) and
ampliﬁcation (p) factors were initially both set equal to unity.
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function value and by visual inspection of the post-rebound oscillations.
The mixed-effects modeling of NiAc exposure and NEFA data was done by
means of NONMEM (Version VI level 2.1, Icon Development Solutions, Maryland,
USA). The Laplacian estimation method was used throughout the model-building
process. Interindividual variability was modeled as exponential models for all
disposition parameters of NiAc and NEFA and the random residual variability was
modeled as a function of proportional and additive error for the pharmacokinetics
and pharmacodynamics. The individual disposition parameters of NiAc were
introduced as ﬁxed parameters in the analysis of NEFA data. Model selection was
visually explored in diagnostic plots using Census, version 1.1 (Novartis Pharma
AG, Basel Switzerland) and based on the OFV and precision of parameter estimates.
Results
Disposition analysis of NiAc
Observed plasma concentrations of NiAc following infusions of NiAc are shown in
Fig. 2. The exposure to NiAc at baseline ranged between 0.001 and 0.07 lmol L
-1
and approached 20 lmol L
-1 during the drug infusion regimens. Nonlinear
disposition of NiAc was seen in the experimental data following the highest
30 min infusion dose of 20 lmol kg
-1. The endogenous NiAc concentration was
close to, or below, LLOQ in some animals.
The mixed-effects modeling approach indicated two parallel saturable elimination
processes for NiAc. The major clearance pathway up to approximately 0.1 lmol L
-1
wasofhighafﬁnity(Km1 = 0.00468 lmol L
-1,Vmax1 = 0.0573 lmol min
-1 kg
-1).
At lower concentrations, the second pathway (Km2 = 16.6 lmol L
-1, Vmax2 =
1.46 lmol min
-1 kg
-1) could be approximated to a ﬁrst-order process (Fig. 3). The
two pathways contributed equally at concentrations around 1 lmol L
-1 and above
that concentration the low afﬁnity pathway became the major elimination process.
The endogenous synthesis of NiAc (Synt) was estimated to 0.0346 lmol min
-1 kg
-1
and the endogenous NiAc concentration, calculated according to Eq. 12 in
Appendix A, was estimated to 6.8 nmol L
-1. The shrinkage values were 27% for
Vmax2, 46% for Cld and 48% for Synt. The ﬁnal NiAc disposition parameter
estimates, interindividual variability and their relative standard error (RSE) are
shown in Table 1. The two-compartment turnover model (Fig. 1) described the
experimental data on an individual bases in a consistent manner (see Fig. 4). The
diagnostic plots in Fig. 5 conﬁrmed the consistency of experimental and predicted
NiAc concentrations and there were no marked trends in the residual plots.
Feedback model of NEFA
The observed individual NEFA concentration-time proﬁles obtained after NiAc
infusions are shown in Fig. 6. Baseline NEFA concentrations were consistent in all
animals, and were stable throughout infusion of vehicle in the control animals,
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123ranging between 0.3 and 1.1 mmol L
-1 regardless of infusion duration. Adminis-
tration of NiAc decreased plasma NEFA concentrations to a minimum of
0.055 lmol L
-1. Following cessation of NiAc infusion, there was a rapid return of
NEFA towards baseline, followed by a signiﬁcant rebound which appeared to be
dependent on both the extent and duration of exposure. The amplitude of the rebound
was increased following high NiAc exposure and a post-rebound oscillatory behavior
was seen following long (300 min) infusions. A period of 3–4 half-lives of constant
Fig. 2 Observed plasma NiAc concentration-time proﬁles during and after NiAc infusion. a 30 min
infusion of vehicle (control), or NiAc 1, 5 or 20 lmol kg
-1 of body weight; b 300 min infusion of
vehicle, or NiAc 5, 10 or 51 lmol kg
-1 of body weight. All infusions started at time t = 0 min
J Pharmacokinet Pharmacodyn (2011) 38:1–24 9
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life of ktol (Eq. 30) and the limited resolution of the experimental data during the
30 min infusion, clear adaptation could not be seen.
Figure 7 shows representative individual and population predictions superim-
posed on experimental data after different doses and infusion times. Model-
predicted and experimental data were consistent. The present design showed
adaptation, rebound and post-rebound oscillatory behavior in NEFA concentrations.
The ﬁnal population parameter estimates and interindividual variability are
shown in Table 2. The half-life of the primary effect (t1/2,kout) was estimated to
Fig. 3 Saturable elimination processes identiﬁed in the dispositionof NiAc. The major clearance pathway
up to a concentration of approximately 0.1 lmol L
-1 was high afﬁnity (Km1 = 0.00468 lmol L
-1,
Vmax1 = 0.0573 lmol min
-1 kg
-1). Below that concentration a second pathway (Km2 = 16.6 lmol L
-1,
Vmax2 = 1.46 lmol min
-1 kg
-1) could be approximated to a ﬁrst-order process. The two pathways
contributed equally at concentrations around 1 lmol L
-1 and above that concentration the low afﬁnity
pathway became the major elimination process
Table 1 Final NiAc population pharmacokinetic parameter estimates and interindividual variability
(IIV), with corresponding relative standard errors (RSE%)
Parameter Deﬁnitions Estimate (RSE%) IIV (RSE%)
Vmax1 (lmol min
-1 kg
-1) Maximal velocity, pathway 1 0.0573 (1.57) –
Km1 (lmol L
-1) Michaelis–Menten constant, pathway 1 0.00468 (1.97) –
Vmax2 (lmol min
-1 kg
-1) Maximal velocity, pathway 2 1.46 (4.20) 98.2 (24.8)
Km2 (lmol L
-1) Michaelis–Menten constant, pathway 2 16.6 (6.20) –
Vc (L kg
-1) Volume, central compartment 0.345 (0.559) –
Cld (L min
-1 kg
-1) Intercompartmental clearance 0.0203 (3.08) 54.5 (88.6)
Vt (L kg
-1) Volume, peripheral compartment 3.54 (7.66) –
Synt (lmol min
-1 kg
-1) Endogenous synthesis rate 0.0346 (4.10) 15.8 (62.5)
r1 (%) Residual proportional error 34.4 (18.6) –
r2 (%) Residual additive error 0.800 (5.80) –
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1231.7 min and the half-life of tolerance development (t1/2,ktol) was estimated to
12 min. The shrinkage values were 27% for R0, 13% for kout and 4% for IC50. The
diagnostic plots in Fig. 8 conﬁrmed the consistency of experimental and predicted
NEFA concentrations. There were no marked trends in the residual plots. Random
residual variability was originally modeled as a function of proportional and
additive error. However, as the estimated additive residual error was negligible,
only proportional error was used.
The optimal number of moderator transit compartments N was estimated to be 8.
The equilibrium NiAc concentration-NEFA response relationships of both a
tolerant and non-tolerant system (Fig. 9) were simulated using the ﬁnal parameter
estimates (Table 2, Eqs. 13–20 in Appendix B). In the tolerant system the
Fig. 4 Representative model ﬁts of NiAc plasma concentration-time data at different durations (30 min
(left) and 300 min (right)) and rates of NiAc infusion. Solid and dashed lines represents individual and
population ﬁts, respectively. Infusion started at time t = 0 min. Plots of all individual regressions are
available from the author upon request
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123relationship was shallower (shifted upwards) and shifted to the right compared to a
non-tolerant system.
Discussion
NiAc treatment has been reported to decrease cardiovascular events such as
myocardial infarction and death [5–7] by altering the lipoprotein proﬁle in the
circulation. When NiAc binds to the G-protein-coupled receptor GPR109A in
adipocytes, the hydrolysis of TG to NEFA and glycerol is inhibited. The decreased
plasma NEFA concentrations are followed by a decrease in plasma TG, very-low-
density lipoproteins (VLDL) and LDLs, and an increase in plasma HDLs [7, 8].
Fig. 5 Goodness-of-ﬁt plots for NiAc. Measured concentrations were plotted against population ﬁtted
concentrations (a) and individually ﬁtted concentrations (b) on a logarithmic scale. Individually weighted
residuals were plotted against time (c), and against individually ﬁtted NiAc concentrations on a semi-
logarithmic scale (d). Conditional weighted residuals were plotted against time (e), and against
population ﬁtted concentrations (f)
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123However, use of NiAc is limited because it is associated with a substantial rebound
of plasma NEFA concentrations above baseline levels, increasing the risk of
myocardial ischemia [1, 2]. For this reason, there is a need to better understand the
mechanisms behind the complex regulation of plasma NEFA metabolism and its
feedback mechanisms (e.g. insulin). This is particularly so in a drug discovery
Fig. 6 Observed plasma NEFA concentration-time proﬁles during and after a a 30 min infusion of
vehicle or NiAc (1, 5 or 20 lmol kg
-1 of body weight), and b a 300 min infusion of vehicle or NiAc (5,
10 or 51 lmol kg
-1 of body weight). The NEFA concentrations in each one of the control animals were
stable but a large variability could be seen between the animals. All infusions started at time t = 0 min
J Pharmacokinet Pharmacodyn (2011) 38:1–24 13
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vivo models. For example, potential functional adaptation and rebound need to be
studied during evaluation of NiAc analogues, as these may confound the assessment
of target engagement of new compounds [28]. Thorough quantitative analysis of the
time-course of the plasma NEFA response to NiAc in normal or diseased animals
provides one source of important information about this system.
Since normal animals provide the primary screening model, it was necessary to
ﬁrst investigate the disposition of NiAc at pharmacological exposure levels.
Exposure to NiAc ranged from 0.001 to about 20 lmol L
-1 in the infusion groups
(Fig. 2), and disposition was clearly nonlinear following the highest 30 min infusion
(20 lmol kg
-1). We successfully ﬁtted a two-compartment model with two parallel
capacity-limited elimination processes, corresponding to glycine conjugation and
Fig. 7 Representative model ﬁts of NEFA plasma concentration-time data after different durations
(30 min (left) and 300 min (right)) and rates of NiAc. Solid and dashed lines represent individual and
population ﬁts, respectively. Infusion started at time t = 0 min. Plots of all individual regressions are
available from the author upon request
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123amidation, and endogenous synthesis to the NiAc data. Although a model with dual
saturable elimination pathways was proposed by Iwaki et al. [29], their model failed
to converge. The glycine conjugation forming nicotinuric acid (NiUAc) was shown
by Iwaki et al. to be capacity-limited, and there was also weak evidence that the
amidation pathway was capacity-limited. Because a two-compartment model with a
single capacity-limited elimination pathway failed in our study, we used a model
with two parallel capacity-limited pathways. The estimates of Vmax and Km were
0.0573 lmol min
-1 kg
-1 and 0.00468 lmol L
-1 for the high afﬁnity process, and
1.46 lmol min
-1 kg
-1 and 16.6 lmol L
-1 for the low afﬁnity process. The high
afﬁnity/low capacity process was the major clearance pathway up to approximately
0.1 lmol L
-1 and the two processes contributed equally at concentrations
around 1 lmol L
-1 (Fig. 3). Iwaki et al. [29] obtained a Vmax and Km of
1.9 lmol min
-1 kg
-1 and 39 lmol L
-1, respectively. The discrepancy in Km may
be due to the different concentration ranges (Iwaki et al. approximately
0.8–800 lmol L
-1, present study approximately 0.001–20 lmol L
-1), with the
estimated Km2 value in our study being close to the highest measured NiAc
concentration. In addition, Iwaki et al. did not include an endogenous synthesis
parameter, nor did they use a mixed-effects modeling approach. The use of different
rat strains (Wistar by Iwaki et al., Sprague-Dawley in the present study) and
nutritional state are also potential sources of variation between these two studies.
Finally, the LLOQ was 0.001 lmol L
-1 in our study, and 0.8 lmol L
-1 in the
Iwaki et al. study.
The disposition model described the observed individual NiAc data accurately
and the model parameters were estimated with good precision. The interindividual
variability in some parameters was large. However, the experimental NiAc
concentration-time proﬁles in Fig. 2 showed large interindividual variability in
concentration both at baseline and at steady state. The individually predicted NiAc
Table 2 Population pharmacodynamic (NEFA response) parameter estimates and interindividual vari-
ability (IIV) with corresponding relative standard errors (RSE%)
Parameter Deﬁnitions Estimate (RSE%) IIV (RSE%)
R0 (mmol L
-1) Baseline NEFA concentration 0.606 (3.51) 29.0 (43.1)
kout (L mmol
-1 min
-1) Fractional turnover rate 0.411 (9.22) 48.2 (35.6)
ktol (min
-1) Turnover rate of moderator 0.0267 (3.40) –
c Sigmoidicity factor 1.48 (3.79) –
IC50 (lmol L
-1) Potency 0.0446 (7.20) 101 (46.1)
p Ampliﬁcation factor 1.21 (6.64) –
kcap (mmol L
-1 min
-1) Formation of NEFA in capillaries 0.0318 (6.51) –
kin (mmol
2 L
-2 min
-1) Turnover rate of NEFA 0.0650 –
t1/2,kout (min) Half-life of primary response 1.69 –
t1/2,ktol (min) Half-life of tolerance 11.7 –
Imax Efﬁcacy 1 –
r (%) Residual proportional error 22.1 (8.51) –
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and therefore fulﬁlled its primary objective as a smoothing function.
We estimated endogenous synthesis of NiAc (Synt)t ob e0 . 0 3 4 6lmol min
-1 kg
-1
(population range 0.0297–0.0439 lmol min
-1 kg
-1), resulting in a baseline con-
centration of 6.8 nmol L
-1 (population range 4.8–15 nmol L
-1). However, the
endogenous concentration of NiAc was not measurable in all predose and control
group samples which may have biased the results.
Infusion of NiAc effectively decreased the plasma NEFA concentration in rats to
around 10% of the predose baseline level (Fig. 6). Increasing the infusion rate from
0.17 to 0.67 lmol min
-1 kg
-1 did not further decrease NEFA concentrations. This
suggests a lower limit of NEFA concentrations at 0.055 lmol L
-1. After stopping
NiAc infusion, plasma NEFA concentrations increased 18–260% above baseline.
Fig. 8 Goodness-of-ﬁt plots for NEFA. Measured concentrations were plotted against population ﬁtted
concentrations (a) and individually ﬁtted concentrations (b) on a logarithmic scale. Individual weighted
residuals were plotted against time (c), and against individually ﬁtted NEFA concentrations on a semi-
logarithmic scale (d). Conditional weighted residuals were plotted against time (e), and against
population ﬁtted concentrations (f)
16 J Pharmacokinet Pharmacodyn (2011) 38:1–24
123During the 300 min infusions the slowly developing tolerance gave rise to
increasing NEFA concentrations despite constant exposure to NiAc. Finally, there
was an oscillatory pattern during the decline of the rebound, particularly after the
extended infusions.
To characterize NiAc-induced changes in plasma NEFA concentrations, we have
developed a mathematical model based on feedback coupled to a series of
moderator transit compartments, with the ﬁrst moderator compartment acting
negatively on the formation of response, and the last acting positively on loss of
response. It is well-known that insulin is involved in the regulation of NEFA;
rapidly by inhibiting the hydrolysis of TG to NEFA and glycerol [24, 25, 27] and by
stimulating the re-esteriﬁcation of NEFA to TG by means of a more slowly
regulated process [24–27]. The transit compartment approach is a well established
tool for describing delays caused by transduction processes between a biosignal and
dynamic responses [30]. The proposed feedback model mimics the observed
complex NEFA pattern with regard to tolerance during NiAc exposure, rebound,
and the oscillatory return of NEFA towards its predose baseline concentration upon
cessation of NiAc treatment. The parameters showed low correlation and shrinkage
and could be estimated with high precision. No obvious trends were seen in the
goodness-of-ﬁt-plots (Fig. 8).
The NEFA response-time data were initially analyzed by means of a pool/
precursor model [10–12]. Since the basic pool/precursor model predicts equal
response and rebound areas, cannot separate response at steady state from baseline,
lacks the characteristics of a dampened system, and gave systematic deviations
between observed and predicted data, it was discarded at an early state. An
alternative way to describe the dual-action of the moderator (e.g. insulin)
mechanistically would be to include two parallel moderators, each with its own
rate constants. One disadvantage of the latter approach compared to the model in
Fig. 1 is the increased number of parameters. However, the model with parallel
Fig. 9 Simulated steady state plasma NiAc concentration versus plasma NEFA concentration (Rss). The
solid line represents the tolerant system according to Eq. 15, and the dashed line the non-tolerant system
according to Eq. 17. The ﬁnal parameter estimates from Table 2 were used to draw the two curves
J Pharmacokinet Pharmacodyn (2011) 38:1–24 17
123moderators also failed to adequately mimic the oscillations seen in the rebound after
extended infusions of NiAc.
The population mean estimate of NiAc potency (IC50) was 45 nmol L
-1 (±7.2%
RSE) which was six times higher than the endogenous concentration estimate of
NiAc (7 nmol L
-1). The range of individually predicted endogenous NiAc
concentrations was 5–15 nmol L
-1 and below the NiAc potency. The lower limit
of plasma NEFA concentrations was captured by means of a separate parameter
kcap, mimicking the non-adipocyte release of NEFA into plasma. This parameter
represents the hydrolysis of TG to NEFA and glycerol in the capillaries and is
affected neither by NiAc nor by the moderator. Because this lower limit is seen
following administration of other GPR109A agonists (e.g. acipimox [31]), it is
suggested to be a system- rather than a drug-speciﬁc parameter, so replacing kcap
with Imax in the drug mechanism function (Eq. 2) would not be mechanistically
correct. Simultaneous estimation of kcap and Imax would be difﬁcult since both of the
parameters are determined from the minimum response and will therefore be highly
correlated unless data of both full and partial agonists are evaluated simultaneously.
Hence, the Imax parameter was ﬁxed to unity in the analysis. The exponent p of the
ﬁrst moderator M1, which was added to amplify the impact of the negative feedback,
was estimated to 1.2 (±6.6% RSE), which is statistically signiﬁcant different from
unity (1) based on the 95% conﬁdence interval of the parameter estimate. The half-
life of the primary effect t1/2,kout was predicted to 1.7 min and the half-life of
tolerance development t1/2,ktol to 12 min. Although there is no generic design of
experiments aimed at capturing tolerance development, multiple provocations for at
least 3–4 t1/2,ktol, coupled to washout dynamics with sufﬁcient baseline data, are
commonly recommended [32].
Ideally, the number of transit compartments should be estimated as a parameter
in the model, as this makes it possible to add interindividual variability of the
number of compartments, as shown by Sun and Jusko [30] and Savic et al. [33].
However, because their approaches were based on the assumption that there was no
continuous input to the ﬁrst transit compartment, they could not be applied to our
system. Thus, the optimal number of compartments was estimated to be eight by
manually increasing N until the best ﬁt and minimum OFV was established. By
increasing N, the oscillatory behavior of the response became more pronounced.
When N was less than six, the oscillatory rebound was not adequately captured,
which also resulted in an increased OFV.
In the present analysis tolerance was assumed to be due to physiological
adaptation or homeostatic counter-regulation, originating from the reduction in the
plasma concentration of NEFA. An effective way to show the extent of tolerance is
to derive the concentration-response relationship at equilibrium. That the steady
state condition of the system exhibiting tolerance differed from the non-tolerant
system can be seen in Fig. 9, with the equilibrium curve of the tolerant system being
shallower and shifted to the right. The size of the shift provides a convenient and
informative measurement of the impact of tolerance and is especially important for
an accurate estimate of potency. If tolerance is ignored, dose predictions may fail,
leading to under-prediction of the actual dose needed.
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earlier experiments [18] were not designed to support a quantitative analysis of
NEFA turnover, and also lacked NiAc concentration-time data. The amount of drug
in the biophase was assumed to drive the pharmacodynamics and a ﬁrst-order
elimination rate constant of NiAc from the biophase was estimated in the modeling
of pharmacodynamic data [18]. The potency estimate from that study [18] appeared
to be similar to that in the present analysis (IC50 value of 38 nmol L
-1 ±31% RSE
versus 45 nmol L
-1 ±7.2% RSE, respectively). However, the more robust design in
the present study yielded higher parameter precision and valuable information about
the system, such as the slowly developing tolerance and the oscillatory decline in
the rebound following long infusions of NiAc. Furthermore, determining the plasma
exposure to NiAc gave direct information about potency and efﬁcacy, and their
relation to safety, and established target engagement.
Overall, the individual predictions provided a good description of the shape of
the observed responses. Not only was parameter precision high, but the parameters
obtained were independent of the extent and duration of exposure. Ideally, all
components known to be involved in the regulation of NEFA (e.g. insulin, glucose,
TG, growth hormone, and glucagon) should be observed experimentally and
modeled simultaneously with the NEFA-time data. However, for the purpose of
assessing the rate and extent of tolerance development and rebound after acute
dosing, the present model sufﬁces.
This study shows that it is possible to predict the time-course of drug effects
in vivo in situations where feedback mechanisms are operative. The proposed
model may serve as a preclinical tool for predicting and analyzing changes in
plasma NEFA concentrations after treatment with NiAc or NiAc analogues [28].
Sparse sampling of a follow-up compound may sufﬁce, provided the system
parameters have been accurately characterized. This allows a smoother drug
selection process.
Appendix A: disposition of NiAc
The disposition of NiAc at baseline was described by:
VC
dCp
dt
¼ Synt  
Vmax1
Km1 þ CpBaseline
CpBaseline  
Vmax2
Km2 þ CpBaseline
CpBaseline
  CldCpBaseline þ CldCtBaseline ¼ 0
Vt
dCt
dt
¼ CldCpBaseline   CldCtBaseline ¼ 0
8
> > > > > <
> > > > > :
ð9Þ
Equation 9 were rearranged to yield the expression:
Synt  
Vmax1
Km1 þ CpBaseline
CpBaseline  
Vmax2
Km2 þ CpBaseline
CpBaseline ¼ 0 ð10Þ
or
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pBaseline þ Synt Km1 þ Km2 ðÞ   Vmax1Km2   Vmax2Km1 ðÞ CpBaseline
þ SyntKm1Km2 ¼ 0 ð11Þ
The solution to this quadratic equation is:
CpBaseline ¼
 b  
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
b2   4ac
p
2a
ð12Þ
where
a ¼ Synt   Vmax1   Vmax2; b ¼ Synt Km1 þ Km2 ðÞ   Vmax1Km2   Vmax2Km1;
c ¼ SyntKm1Km2
There was only one positive root to Eq. 12, providing the estimate of CPBaseline.
Appendix B: derivation of steady state conditions
Derivations were used to determine the steady state response Rss and the plasma
concentration Cp for the tolerant model (Eqs. 3, 4) and for the corresponding non-
tolerant model:
dR
dt
¼ kinIC p
  
þ kcap   koutR ð13Þ
where the drug mechanism function I(Cp) is given by Eq. 2.
For the model involving tolerance, formulated in Eqs. 3 and 4, the steady state
values for the response R and the moderators Mi (i ¼ 1;...;N) are given by:
R ¼ M1 ¼   ¼ MN ¼ Rss ð14Þ
where Rss is the unique solution of the equation:
kin
R
p
ss
IC p
  
þ kcap   koutR2
ss ¼ 0 ð15Þ
in which
kin ¼ koutR2
0   kcap
  
R
p
0 ð16Þ
and R0 is the baseline response.
In the absence of tolerance, Rss needs to satisfy:
kinIðCpÞþkcap   koutRss ¼ 0 ð17Þ
where
kin ¼ koutR0   kcap ð18Þ
Note that since Imax = 1, it follows from the deﬁnition (Eq. 2)o fI(Cp) that IC p
  
!
0a sCp ? ?. This implies that:
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Cp!1
Rss Cp
  
¼
kcap
kout
   1=2
tolerant ð19Þ
lim
Cp!1
Rss Cp
  
¼
kcap
kout
non   tolerant ð20Þ
Appendix C: derivation of ktol and its half-life
If exposure is sufﬁciently long, the response and moderators will all reach their
steady state Rss = Mss, where Mss is the steady state for each of the N = 8
moderators. Upon washout, because of the delay caused by the cascade, it takes time
for the last moderator, M8 to depart from its steady state, so M8(t) & Mss.
Therefore, in the early stages of the washout period, the dynamics is effectively
described by the system:
dR
dt
¼
kin
M
p
1
þ kcap   koutRMss
dM1
dt
¼ ktol R   M1 ðÞ
8
> > <
> > :
ð21Þ
which involves R and M1 only. It is this simpler system which describes the rebound
and the initial period of the return to baseline.
Derivation of the baseline
It is important to notice that the baseline Rb of the system (i.e., immediately after
washout; Eq. 21) is different, and in fact higher, than the baseline R0 of the full
system described by Eqs. 3 and 4. To demonstrate this, we observe that Rb and R0
satisfy the following expressions, respectively:
kin
R
p
b
þ kcap   koutRbMss ¼ 0
kin
R
p
0
þ kcap   koutR2
0 ¼ 0
ð22Þ
so that:
kin
R
p
b
 
kin
R
p
0
¼ kout RbMss   R2
0
  
ð23Þ
Suppose that Rb B R0, then the left-hand side of Eq. 23 is non-negative, whilst the
right-hand side is negative, because Mss\R0. Because this is a contradiction,
Rb[R0, as asserted.
Derivation of ktol
If ktol is small compared to koutMss, the proposal of Gabrielsson and Peletier [17]
shows that R and M1 are in quasi-equilibrium; that is,
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1
koutMss
kin
M
p
1 t ðÞ
þ kcap
  
 
~ R
pþ1
b
M
p
1 t ðÞ
ð24Þ
where
~ R
pþ1
b ¼
kin
koutMss
ð25Þ
because kcap is small. Note that ~ Rb   Rb.
Substituting this approximate expression for R into the equation for M1 in Eq. 21,
gives:
dM1
dt
¼ ktol
~ R
pþ1
b
M
p
1
  M1
 !
ð26Þ
By multiplying this equation by M
p
1and writing M
pþ1
1 ¼ y, we obtain:
dy
dt
¼ 1 þ p ðÞ ktol ~ R
pþ1
b   y
  
ð27Þ
so that:
yt ðÞ¼M
pþ1
1 t ðÞ¼~ R
pþ1
b 1 þ Be  pþ1 ðÞ ktolt
  
ð28Þ
where B is a constant factor. Therefore, as t ? ?:
M1 t ðÞ ~ Rb ¼ Oe   pþ1 ðÞ ktolt
  
ð29Þ
Thus, M1(t) and hence R(t), converge towards the local baseline with a half-life
given approximately by:
t1=2;ktol  
ln 2 ðÞ
p þ 1 ðÞ ktol
ð30Þ
We assume that an initial estimate of ktol may be approximated from the log-linear
decline of NEFA post-rebound time-course.
We conclude that by estimating the half-life of the return to baseline after the
rebound, we can obtain a ﬁrst estimate of ktol.
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